FIELD: medicine.
SUBSTANCE: invention refers to the use of reserpine as an agent possessing anti-inflammatory and antifibrotic action in pulmonary tissue, and cytostatic action.
EFFECT: extended range of products used for pharmacological correction of pulmonary inflammation and fibrosis accompanying cytostatics prescribed.
1 dwg, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IMPROVING THERAPEUTIC EFFECTIVENESS IN LUNG TISSUE DISORDERS AFTER ACTION OF CYTOSTATICS | 2012 |
|
RU2497523C1 |
| AGENT PREVENTING DEVELOPING DISORDERS IN PULMONARY TISSUE AND BLOOD SYSTEM ACCOMPANYING CYTOSTATIC ACTION | 2011 |
|
RU2464983C1 |
| AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2013 |
|
RU2530651C1 |
| METHOD OF TREATING PULMONARY FIBROSIS | 2012 |
|
RU2494470C1 |
| PREPARATION PREVENTING DEVELOPMENT OF ABNORMALITIES IN LUNG TISSUE UNDER CYTOSTATIC IMPACT | 2011 |
|
RU2455991C1 |
| METHOD OF DETERMINING EFFICACY OF HAEMOSTIMULATORS IN CYTOSTATIC MYELOSUPPRESSION | 2009 |
|
RU2421720C2 |
| METHOD OF GRANULOCYTOPOIESIS DEPRESSION CORRECTION IN CYTOSTATIC ACTION | 2008 |
|
RU2366422C1 |
| AGENT FOR CORRECTING PULMONARY TISSUE DISORDERS UNDER CYTOSTATIC EXPOSURE | 2013 |
|
RU2554776C1 |
| MEANS FOR PNEUMOFIBROSIS PREVENTION AND TREATMENT AND METHOD FOR ITS PRODUCTION | 2016 |
|
RU2646810C1 |
| MEANS FOR CORRECTION OF VIOLATIONS IN HEMOGENESIS ERYTHROID LINEAGE CAUSED BY CYSTOSTATIC IMPACT | 2016 |
|
RU2634572C1 |
